

Application No. 10/734,149
Response dated July 15, 2005
Response to Action of June 15, 2005

- 2 -

Amendments to the claims

This list of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

Claims 1 to 9 (canceled)

10. (currently amended) The method of claim 16, wherein the polypeptide and antigen are provided in a [[A]] kit for the preparation of a vaccination comprising a predetermined amount of [[an]] the antigen and a predetermined amount of [[a]] the polypeptide of claim 4.

11. (currently amended) The method of claim 33, wherein the polypeptide and antigen are provided in a [[A]] kit for the preparation of a vaccination comprising a predetermined amount of the [[an]] antigen and a predetermined amount of the [[a]] polypeptide of claim 4.

12. (currently amended) The method of claim 34, wherein the polypeptide or variant thereof and antigen are provided in a [[A]] kit for the preparation of a vaccination comprising a predetermined amount of the [[an]] antigen and a predetermined amount of the [[a]] polypeptide or variant thereof of claim 5.

13. (currently amended) The method of claim 35, wherein the polypeptide or variant thereof and antigen are provided in a [[A]] kit for the preparation of a vaccination comprising a predetermined amount of the [[an]] antigen and a predetermined amount of the [[a]] polypeptide or variant thereof of claim 6.

14. (currently amended) The method of claim 36, wherein the polypeptide or variant thereof and antigen are provided in a [[A]] kit for the preparation of a vaccination comprising a predetermined amount of the [[an]] antigen and a predetermined amount of the [[a]] polypeptide or variant thereof of claim 7.

Application No. 10/734,149
Response dated July 15, 2005
Response to Action of June 15, 2005

- 3 -

15. (canceled)

16. (currently amended) A method of vaccinating a patient comprising administering an antigen other than CD14 and a polypeptide of claim 4 to the patient, wherein the polypeptide activates B cells, and is encoded by a nucleotide sequence that has at least 62.6% identity with SEQ ID NO:1 and that hybridizes thereto under high stringency conditions which include a wash step in 0.1xSSC, 1% SDS at 65°C for 3 hours.

Claims 17 to 32 (canceled)

33. (new) The method of claim 16, wherein said identity is at least 74.2% identity.

34. (new) The method of claim 16, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, a conservatively substituted variant thereof which activate B cells, a fragment of a said sequence which activates mammalian B cells, or a conservatively substituted variant of a said fragment which activates mammalian B cells.

35. (new) The method of claim 33, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, a conservatively substituted variant thereof which activate B cells, a fragment of a said sequence which activates mammalian B cells, or a conservatively substituted variant of a said fragment which activates mammalian B cells.

36. (new) The method of claim 34, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, a conservatively substituted variant thereof which activate B cells, or a fragment of a said sequence which activates mammalian B cells.

37. (new) The method of claim 35, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, a conservatively

Application No. 10/734,149
Response dated July 15, 2005
Response to Action of June 15, 2005

- 4 -

substituted variant thereof which activate B cells, or a fragment of a said sequence which activates mammalian B cells.

38. (new July 2005 – based on original claim 1 and 16) The method of claim 36, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, or a conservatively substituted variant thereof which activate B cells.

39. (new July 2005 – based on original claim 1 and 16) The method of claim 37, wherein the polypeptide includes the amino acid sequence identified as SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, or a conservatively substituted variant thereof which activate B cells.

40. (new) The method of claim 16, wherein the polypeptide comprises the amino acid sequence identified as SEQ ID NO:4.

41. (new) The method of claim 16, wherein the polypeptide comprises the amino acid sequence identified as SEQ ID NO:5.

42. (new) The method of claim 16, wherein the polypeptide comprises the amino acid sequence identified as SEQ ID NO:6.

43. (new) The method of claim 16, wherein the antigen and the polypeptide are conjugated to each other.

44. (new) The method of claim 33, wherein the antigen and the polypeptide are conjugated to each other.

45. (new) The method of claim 34, wherein the antigen and the polypeptide are conjugated to each other.

46. (new) The method of claim 35, wherein the antigen and the polypeptide are conjugated to each other.

Application No. 10/734,149
Response dated July 15, 2005
Response to Action of June 15, 2005

- 5 -

47. (new) The method of claim 36, wherein the antigen and the polypeptide are conjugated to each other.
48. (new) The method of claim 37, wherein the antigen and the polypeptide are conjugated to each other.
49. (new) The method of claim 38, wherein the antigen and the polypeptide are conjugated to each other.
50. (new) The method of claim 39, wherein the antigen and the polypeptide are conjugated to each other.
51. (new) The method of claim 40, wherein the antigen and the polypeptide are conjugated to each other.
52. (new) The method of claim 41, wherein the antigen and the polypeptide are conjugated to each other.
53. (new) The method of claim 42, wherein the antigen and the polypeptide are conjugated to each other.
54. (new) The method of claim 16, further comprising the step of mixing the antigen and said polypeptide vaccine prior to the administering step.
55. (new) The method of claim 16, wherein the polypeptide is recombinant.
56. (new) The method of claim 16 wherein the administering step includes administering the polypeptide in combination with a pharmaceutical excipient.
57. (new) The method of claim 37, wherein the polypeptide or variant thereof and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide or variant thereof.

Application No. 10/734,149
Response dated July 15, 2005
Response to Action of June 15, 2005

- 6 -

58. (new) The method of claim 38, wherein the polypeptide or variant thereof and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide or variant thereof.

59. (new) The method of claim 39, wherein the polypeptide or variant thereof and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide or variant thereof.

60. (new) The method of claim 40, wherein the polypeptide and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide.

61. (new) The method of claim 41, wherein the polypeptide and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide.

62. (new) The method of claim 40, wherein the polypeptide and antigen are provided in a kit for the preparation of a vaccination comprising a predetermined amount of the antigen and a predetermined amount of the polypeptide.